GHIDUL TERAPIEI ANTIRETROVIRALE LA COPIL 2013 ȘCOALA MEDICALĂ DE VARĂ IUNIE IAȘI

Similar documents
Progrese in Vaccinologie

Josep Mallolas Hospital Clínic Barcelona

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

What are the most promising opportunities for dose optimisation?

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Medical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum

Switching strategies and ARV treatment costs

HIV and contraception the latest recommendations

ASSESSMENT OF VACCINE EFFICACY FOR DISEASES INCLUDED IN THE NATIONAL IMMUNIZATION PROGRAM FOR PRESCHOOL CHILDREN

Rajesh T. Gandhi, M.D.

WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?

Second and third line paediatric ART strategies

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Pharmacological considerations on the use of ARVs in pregnancy

Somnuek Sungkanuparph, M.D.

Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa

PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT

15 years Follow Up in a Cohort of Children diagnosed with HIV Cardiomyopathy

First-Line Antiretroviral Therapy for Treatment and Prevention:

Overview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014

The evolution of HIV/AIDS Epidemic in Romania 31 December 2013

Fat redistribution on ARVs: dogma versus data

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

The evolution of HIV/AIDS infection in Romania 31 December 2017

Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)

Asociatia pentru Servicii Mobile de Ingrijire Paliativa in 2010

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

Cases from the Clinic(ians): Case-Based Panel Discussion

in practical activity

Clinical cases: HIV/HCV coinfection

Electroencephalography (EEG) alteration in Autism Spectum Disorder (ASD)

HIV infection in children. Mariana Mardarescu MD PhD,

MANAGING HIV IN CHILDREN: BEST PRACTICES

2016 Perinatal Treatment Guidelines Update

The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases

HIV und AIDS- was gibt es Neues für die Arbeit vor Ort?

The impact of antiretroviral drugs on renal function

European Guidelines. for the Clinical Management and Treatment of HIV Infected Adults

What's new in the WHO ART guidelines How did markets react?

Comprehensive Guideline Summary

Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town

CHANGES INDUCED BY THE ADDED FAT IN THE BROILERS FODDER ON THE SERIQUE LEVELS OF THE GALL PIGMENTS

Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

RAPORT DE EVALUARE A TEHNOLOGIILOR MEDICALE

When to Start HIV Treatment? Which Treatments to Start?

What next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute

the future and the past are the leaf s two faces

Using new ARVs in pregnancy

Caring for HIV infected patients in Spain during the current economical crisis

BHIVA antiretroviral treatment guidelines 2015

CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs

HIV Treatment: New and Veteran Drugs Classes

HIV and Paediatrics in Central Europe

Treatment Optimisation Community Condultation Feedback. KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016

Quality of medical services and their impact on the cascade of cares in HIV infection, at national level Roundtable discussion

Utilizare ecard in aplicaţie de raportare pentru medicii de Dializa

ART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS)

Antiretroviral Drugs

New Directions on WHO ARV Guidelines 2018

2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall

Existing and most needed paediatric ARV formulations

30 years of HIV experience in Romania

Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi

New Frontiers for Treatment Strategies for HIV Care

TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES

Constructing antiretroviral regimens to overcome imperfect adherence

Progress toward Universal ART Access: Innovations and Treatment 2.0. Marco Vitoria World Health Organization September 2013

Paediatric ART Working Group. guideline review meetings

Management of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie

Understanding the unmet medical needs with current ART

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013

Tunisian recommendations on ART : process and results

Professor José Arribas

Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya

Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use

BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI. Medicamentul nu mai este autorizat

Susan L. Koletar, MD

EACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director. Faculty

Clinical Pharmacology and Formulation Challenges of Pediatric Antiretroviral Treatment

INTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY

Sex differences in HIV-1 viral load and absolute CD4 cell count in long term survivors HIV-1 infected patients from Giurgiu, Romania

Viral hepatitis in patients living with HIV: can we still speak of special population?

When to Rock the Boat Switching Antiretroviral Therapy for Metabolic Complications

PROSPECT: INFORMAŢII PENTRU UTILIZATOR. Granisetron Kabi 1 mg/ml, soluţie injectabilă Granisetron

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter

Paediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016

HIV Treatment: State of the Art 2013

PACHETE DE PROMOVARE

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

Advances in HIV science and treatment. Report on the global AIDS epidemic,

Is current first line ART good enough? Francois Venter Wits Reproductive Health & HIV Research Institute

Kiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre

Knežević-Pogančev M. Trombocitopenie izolată provocată de Valproat în urma episoadelor febrile...

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia

Optimizing Paediatric and Adolescent ART: Challenges and Opportunities

Transcription:

GHIDUL TERAPIEI ANTIRETROVIRALE LA COPIL 2013 ȘCOALA MEDICALĂ DE VARĂ 13-15 IUNIE IAȘI

MATERIAL REALIZAT ÎN SECȚIA IMUNODEPRESIE COPII ȘI ADOLESCENȚI A I.N.B.I.-BUCUREȘTI Dr.Mariana Mărdărescu Dr.Cristina-Roxana Petre Dr.Sorin Petrea Dr.Ruxandra Neagu-Drăghicenoiu Dr.Rodica Ungurianu Dr. Ana Maria Tudor Dr.Alina Maria Cibea Psih.Carina Matei CU SPRIJINUL COMPARTIMENTULUI PENTRU MONITORIZAREA ŞI EVALUAREA INFECŢIEI HIV/SIDA ÎN ROMÂNIA-I.N.B.I. ȘI CENTRULUI ROMÂN HIV/SIDA...Mulțumim întregului colectiv implicat în îngrijirea copiilor și adolescenților expuși/infectați HIV

Obiectivele TARV Obținerea succesului o virusologic (ARN HIV nedetectabil) o imunologic (nivele normale ale CD4), Preverirea afecțiunilor oportuniste cu prețul unor reacții adverse cât mai reduse. Identificarea, instruirea și implicarea părintelui / tutorelui în administrarea corectă a tratamentului.

Criterii de inițiere TARV Vârsta 0-12 luni Peste 12 luni Clinic indiferent Stadiul OMS 3, 4 sau CDC B,C Nivelul CD4 indiferent Sub 25% ARN HIV indiferent Peste 100000c/ml

Combinatii recomandate Vârsta Preferat Alternativa < 5 ani 2INRT (ABC+3TC) + 1INNRT (NVP) 5 6 ani 2INRT (ABC+3TC) + 1INNRT (NVP) >6 ani 2INRT (ABC+3TC) + 1INNRT (EFV) 2INRT (ZDV+3TC/ZDV+ABC) + IP (LPV/r) 2INRT (ZDV+3TC/ZDV+ABC) + II* (RAL) 2INRT (ZDV+3TC/ZDV+ABC) + 1INNRT(EFV) 2INRT (ZDV+3TC/ZDV+ABC) + IP (LPV/r) 2INRT (ZDV+3TC/ZDV+ABC) + II* (RAL) 2INRT (ZDV+3TC sau ZDV+ABC) + 1INNRT (NVP) 2INRT (ZDV+3TC sau ZDV+ABC) + IP LPV/r, ATV/r dacă G peste 15 kg, FPV/r dacă G peste 32kg, DRV/r dacă G peste 40 kg) 2INRT (ZDV+3TC sau ZDV+ABC) + II* (RAL)

Tratament ARV după eșecul primei linii terapeutice Prima linie terapeutică A doua linie terapeutică Comentarii 2 INRT + 1 INNRT 2 INRT + 1 IP/r sau II* Test de rezistență recomandat *3TC+ZDV *3TC+ABC ABC+ddI/3TC TDF+ABC/3TC/FTC (>12ani) ZDV+ddI/3TC TDF+ZDV/3TC /FTC (>12ani) Dacă nu este disponiibil se recomandă 2INRT+1IP/r (de preferat LPV/r; la copiii mai mari se pot utiliza și: ATV/r, DRV/r, FPV/r; SQV/r; TPV/r). 2 INRT + 1 IP/r 2 INRT + 1 INNRT sau + 1 II* Eșecul este în general secundar unui deficit de aderență. 3 INRT (situații excepționale) Regim combinat INRT/INNRT/IP/II* De preferat o schemă cu IP/r

Vaccinarea la copilul expus sau cu infectie HIV Calendarul naţional de vaccinare 2013 ordinul MS 897/2012, si vaccinările optionale vârsta vaccinul comentarii Primele 24 de ore, 2-7 zile Primele 24 de ore 2-7 zile BCG, Hep B în maternitate; Se poate amâna la prematuri în maternitate 2 luni DTPa-VPI-Hib-Hep B - la medicul de familie - se administrează simultan - a se utiliza vaccin pertusis acelular 4 luni DTPa-VPI-Hib -la medicul de familie; se administrează simultan 6 luni DTPa-VPI-Hib-Hep B -la medicul de familie, se administrează simultan 12 luni DTPa-VPI-Hib, ROR la medicul de familie, administrare simultan în locuri anatomice diferite 6 ani DTPa-VPI campanii școlare 7 ani ROR campanii școlare 14 ani dt campanii școlare; se vor repeta dozele la fiecare 10 ani, cu verificarea serologiei antitetanice la fiecare 5 ani

Vaccinari opționale Rota Antipneumococic conjugat VZV antihepatita A MenC conjugat HPV Antigripal 3 doze (prima între 6 si 12 săptămâni de viață și ultima înainte de 32 săptămâni de viață) 3 doze înainte de 1 an, apoi o doză între 1-2 ani 2 doze începând cu vârsta de 1 an, la interval de minim 3 luni 2 doze începând cu vârsta de 1 an, la interval de minim 6 luni 3 doze sub vârsta de 1 an, o doză oricând după 1 an la fetițe peste 12 ani, indiferent de valoarea CD4 Începând cu vârsta de 6 luni, anual

Schema de revaccinare a copiilor cu infecție HIV răspunsul postvaccinal se corelează cu CD4 nadir, în cazul anumitor vaccinuri. Imunodepresia severă la prima doza de vaccin face ca răspunsul să fie suboptimal, de aceea se recomandă vaccinarea completă după reconstituirea imună fără imunodepresie imunodepresie ușoară imunodepresie moderată/severă vaccinare conform schemei - dacă nivelul Ac este suboptimal se recomandă revaccinarea - expunere la rujeolă sau varicelă în absența imunității demonstrabile, se vor administra imunoglobuline specifice*, urmate de o doză de vaccin - vaccinurile non-vii (toate, cu excepția BCG, ROR, VZV), pot avea oarecare beneficiu; se vor administra conform schemei -se vor amâna vaccinurile vii 6 luni după normalizarea CD4, similar cu indicația de întrerupere a profilaxiei PCP - revaccinare completă după reconstrucția imună - expunere la rujeolă sau varicelă, se vor administra imunoglobuline specifice în primele 96 ore de la expunere, urmate de o doză de vaccin dupa reconstrucția imună.

Bibliografie selectivă 2012 Revision - Protocol 11. HIV treatment and care for childrenhttp://www.euro.who.int/en/what-we-do/health-topics/communicablediseases/hivaids/publications/2012/ http://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0/ http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/21/hivinfected-adolescents-and-young-adults PENTA 2012 Adherence to ARVT and Acceptability Planned Treatment Interruption in HIV 1 Infected Children Potent and Sustained Antiviral Response of Raltegravir based HAART in HIV 1 Infected Children and Adolescents, Paediatric Infectious Diseases Journal, Vol. 131, No. 3, March 2012 Antiretroviral Treatment for HIV Infection in Adults and Adolescents, 2010 Revision WHO Antiretroviral Treatment for HIV Infection in Infants and Children, 2010 Revision WHO Antiretroviral Treatment of Adult HIV Infection 2010. Recommendation of IAS 2010. Pharmacokinetic, Safety and Efficacy Data on Cohort IIA, Youth Aged 6 11 from IMPAACT P1006: A Phase I / II Study to Evaluate Raltegravir in HIV 1 Infected Youth, CROI 2010. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection preprint of an Article accepted for publication in HIV Medicine 2009, Blackwell Publishingș - http://www.pentatrials.org/guide09.pdf Manual pentru îngrijirea copilului cu HIV, Editie revizuita si adaugita 2004, sub redactia Sorin Petrea.

Vă mulțumesc!